Assertio agrees to $125.1M sale to Garda Therapeutics

Garda Therapeutics agreed to acquire Assertio for $18.00 per share (~$125.1M) plus a contingent value right, representing a 34.6% premium to the Mar 20, 2026 share price and 46.6% to the 30‑day VWAP; the boards approved a tender offer with expected close in Q2 2026 and a 20‑day shop period for superior bids. Assertio concurrently sold several assets to Cosette for $35M upfront (plus earnouts), which Garda says are included in the transaction consideration, and Assertio will delist from Nasdaq after the tender. Operationally Assertio reported a severe Q4 2025 miss: EPS -$1.06 vs -$0.07 expected (surprise -1414%) and revenue $13.54M vs $28.36M expected (-52%); Rolvedon sales fell to $0.4M from $15.4M y/y, while H.C. Wainwright maintained a Buy and $35 price target.

Analysis

The market will now price this as an event-driven takeover where the residual upside is concentrated in closing probability and contingent milestone value rather than core operating improvement. Expect the headline spread to compress quickly if financing signals look clean, while any ambiguity on milestone payouts or buyer covenants will leave a persistent premium to compensate for multi-year tail risk.

Second-order winners are likely to be niche consolidators and outsourced manufacturers that pick up small branded franchises: acquiring these assets can convert episodic cash flows into a stitchable M&A thesis, improving comparability and making those buyers attractive targets themselves. Conversely, specialty wholesalers and certain generics players face nearer-term channel rebalancing as smaller portfolios migrate between owners, which can create transient sell-in/sell-through distortions across quarters.

Primary risks are classical event-driven ones — financing shortfalls, successful superior bids, or protracted disputes over contingent milestones — which would reprice the equity sharply and potentially reopen operating concerns that had been sidelined. Time horizons bifurcate: the arbitrage window is days-to-weeks while meaningful CVR downside / upside plays out over quarters-to-years, so sizing must reflect that calendar mismatch.

Given these mechanics, active strategies should prioritize capped downside and explicit catalyst watches (financing updates, milestone definitions, regulatory flags). Passive holders who cannot tolerate a multi-quarter CVR uncertainty should consider swapping into pure healthcare M&A beneficiaries or hedging via liquid advisor/IB exposure rather than owning the target outright.

Key Decisions for Investors

• Merger-arb with protection (ASRT): Go long ASRT size = 50% of intended event allocation and buy 3-month puts ~10-12% OTM to cap downside. Target return: 4-8% if deal closes inside ~60 days; protected loss limited to ~12-15% if deal breaks. Monitor financing/closing notices daily and reduce size if any buyer-capacity red flags appear.
• Tail hedge (ASRT): Buy longer-dated (9–12 month) OTM puts to cheaply capture low-probability, high-impact deal failure or adverse CVR outcomes. Use this as portfolio insurance against a sector-wide risk-off in small-cap healthcare names.
• M&A-advisor play (MC): Initiate a tactical long on Moelis (MC) on a 3–12 month horizon sized modestly (25% of an event sleeve) to capture fee-flow re-rating from increased healthcare carve-outs. Risk: deal softness or a pause in healthcare M&A that would compress advisor multiples—set a stop if MC underperforms the regional IB peer group by >8% over 30 days.
• Volatility pair on ASRT options: Sell near-term calls (1–2 months) to capture rapid IV decay if the headline spread looks tight, while keeping longer-dated puts as protection. This creates a positive carry trade vs event-decay but requires active monitoring to roll protection if the closing timeline extends.